Who We Are
A national health care company with a patient-centered focus
Gilenya First Dose Observation Program
Concentra has partnered with Novartis to provide a clinical network that administers First Dose Observation (FDO) services required for patients starting therapy on Gilenya (fingolimod). Our Gilenya Assessment Network (GAN) has more than 300 sites nationwide and offers comprehensive clinical services and support for patients on Gilenya.